Compare Victoria's Secret & Co (VSXY) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Victoria's Secret & Co vs Viatris Inc — how do they compare? Victoria's Secret & Co trades at $76 (market cap $6.26B), while Viatris Inc trades at $16.45 (market cap $19.09B). The key difference: Viatris Inc is far larger — about 3× Victoria's Secret & Co's market cap, and Viatris Inc pays a 2.89% dividend while Victoria's Secret & Co pays none. Which is the better fit depends on your goals.
| VSXY | VTRS | |
|---|---|---|
Market Cap | $6.26B | $19.09B |
Sector | Consumer Cyclical | Health |
52-Week High | $99.97 | $17.86 |
52-Week Low | $25.56 | $9.49 |
Enterprise Value | $8.64B | $31.21B |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Victoria's Secret (VSXY) trades at $78.47, up 3.85% with strong earnings momentum after beating Q2 2026 estimates. The stock shows bearish technical signals but maintains solid fundamentals with a 45.27% ROE and improving cash flow projections. Recent news highlights PINK brand growth and beauty segment acceleration, though the stock faces near-term pressure from sales concerns despite earnings outperformance.
The outlook remains cautiously optimistic with a $97.33 consensus price target representing 24% upside potential. Key opportunities include sustained PINK growth and margin expansion, while risks involve competitive pressures and execution challenges. Analyst consensus leans bullish with 60% buy ratings, but investors should monitor Q3 2026 results for confirmation of the turnaround trajectory.
Viatris (VTRS) trades at $16.61, down 1.6% over the past 24 hours. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported a net loss of $3.51 billion in 2025 despite revenue of $14.30 billion, though recent quarters have shown earnings beats. Positive cash flow generation and a dividend payment highlight financial stability, while analyst sentiment is mixed with a majority hold rating.
The outlook for VTRS hinges on its ability to return to profitability and sustain operational improvements. Investment opportunities include strong cash flow, deleveraging progress, and pipeline developments, but risks involve persistent net losses, competitive pressures, and potential regulatory impacts from proposed generic drug tariffs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Victoria's Secret & Co
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
